Cancer cells exhibit a heightened reliance on de novo lipogenesis, even in the presence of abundant extracellular lipids, with key enzymes such as ACLY, ACC1, and FASN identified as promising therapeutic targets [34–36]. Here, ACLY is linked to cancer.